PLx Pharma Inc.’s VAZALORE to Launch in Over 2,400 Rite Aid Stores in August
July 26 2021 - 4:30PM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform to provide more effective and safer products, with its
lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to
together as “VAZALORE”), today announced that three stock-keeping
units (“SKUs”) of VAZALORE, the first and only U.S. Food and Drug
Administration (“FDA”) approved liquid-filled aspirin capsules,
will be available in over 2,400 Rite Aid stores later in August.
Rite Aid is also reserving shelf space with “Coming Soon”
placeholders for all three SKUs -- VAZALORE 81 mg, 12 count;
VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count – to alert
consumers about the new aspirin therapy that will soon be
available.
“Our commercial launch plans are well under way, and we are
delighted that Rite Aid is preparing its stores for VAZALORE later
this summer. We look forward to adding Rite Aid to the growing
number of retail pharmacy leaders that are providing access to this
innovative aspirin therapy,” stated Natasha Giordano, Chief
Executive Officer of PLx.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule that
provides patients with vascular disease and diabetic patients who
are candidates for aspirin therapy based on physician
recommendation, with fast, reliable and predictable platelet
inhibition as compared to enteric-coated aspirin. It also reduces
the risk of stomach erosions and ulcers, as compared to
immediate-release aspirin, common in an acute setting. To learn
more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma Inc. is a specialty pharmaceutical company focused on
its clinically-validated and patent-protected PLxGuard™ drug
delivery platform to provide more effective and safer products. The
PLxGuard drug delivery platform works by targeting the release of
active pharmaceutical ingredients to various portions of the
gastrointestinal (GI) tract. PLx believes this platform has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce the risk of stomach
erosions and ulcers associated with certain drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/63eb4491-f9b7-4c20-9a6b-5cf48bc22c80
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024